Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI

Clinical Cancer Research

Volumn 19, Issue 20, 2013, Pages 5711-5721

  Mittra, Erik S ^a   Fan Minogue, Hua ^a,b   Lin, Frank I ^a   Karamchandani, Jason ^c   Sriram, Venkataraman ^d   Han, May ^e   Gambhir, Sanjiv S ^a,f  

^a Molecular Imaging Program   (United States)

^b System Medicine   (United States)

^c Laboratory of Neuropathology   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e AVEO ONCOLOGY   (United States)

^f STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FICLATUZUMAB; FLUORODEOXYGLUCOSE F 18; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMAGING SYSTEM; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GLIOMA; HEPATOCYTE GROWTH FACTOR; HETEROGRAFTS; HUMANS; LUMINESCENT MEASUREMENTS; MAGNETIC RESONANCE IMAGING; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84886447504     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1015     Document Type: Article

References (10)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975-2008.Bethesda, MD: National Cancer Institute; 2008.
2. Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R. Gliomas in adults. Dtsch Arztebl Int 2010;107:799-807.
3. Patnaik A, Weiss GJ, Papadopoulos K, Tibes R, Tolcher AW, Payumo FC, et al. Phase I study ofSCH900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 2525).
4. Tan E, Park K, Lim WT, Ahn M, Ng QS, Ahn JS, et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol 29: 2011 (suppl; abstr 7571).
5. Kim B, Chenevert TL, Ross BD. Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging. Clin Cancer Res 1995;1:643-50.
6. Gossmann A, Helbich TH, Kuriyama N, Ostrowitzki S, Roberts TP, Shames DM, et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 2002;15:233-40.
7. Veeravagu A, Hou LC, Hsu AR, Cai W, Greve JM, Chen X, et al. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model. Neurol Res 2008;30:952-9.
8. van Furth WR, Laughlin S, Taylor MD, Salhia B, Mainprize T, Henkelman M, et al. Imaging of murine brain tumors using a 1.5 Tesla clinical MRI system. Can J Neurol Sci 2003;30:326-32.
9. Jost SC, Wanebo JE, Song SK, Chicoine MR, Rich KM, Woolsey TA, et al. In vivo imaging in a murine model of glioblastoma. Neurosurgery 2007;60:360-70.
10. Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M, et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 2009;50:36-44.